NCT04541368: Phase 1: A Study of CS1-targeted CAR-T Cells Therapy for RRMM After BCMA CAR-T Thaerapy

• NCT04541368: Phase 1: A Study of CS1-targeted CAR-T Cells Therapy for Relapsed Multiple Myeloma After BCMA CAR-T Cells Therapy

A Study of CS1-targeted CAR-T Cells Therapy for Relapsed Multiple Myeloma After BCMA CAR-T Cells Therapy

Sponsor

Zhejiang University

Collaborator

Yake Biotechnology Ltd.

Chinese Study

---

ClinicalTrials.gov Identifier: NCT04541368

Official Title: Clinical Trial for the Safety and Efficacy of CS1-targeted CAR-T Cells Therapy for Relapsed Multiple Myeloma After BCMA CAR-T Cells Therapy

First Posted: September 9, 2020

Click here to see details on ClinicalTrials.gov

---

Drug: CS1 Targeted CAR T-cells

---

CS1-CAR T Therapy

CS1-CAR T Therapy (Code C155800)

CS1-CAR T Infusion

CS1-CAR T Therapy

CS1-CAR T-cell Therapy

CS1-CAR T-cells

Autologous Anti-CS1 Hinge-optimized CAR-4-1BB-EGFRt-expressing Memory-enriched T-cells (Code C160711)

Anti-CS1 Hinge-optimized CAR-4-1BB-EGFRt-expressing Memory-enriched Autologous T-cells

Anti-CS1 Hinge-optimized CAR-4-1BB-EGFRt-expressing Memory-enriched Autologous T-lymphocytes

Autologous Anti-CS1 Hinge-optimized CAR-4-1BB-EGFRt-expressing Memory-enriched T-cells

Autologous Anti-CS1 Hinge-optimized CAR-4-1BB-EGFRt-expressing Memory-enriched T-lymphocytes

CS1-CAR T-cells

CS1-CAR T-lymphocytes

---

Location

China, Zhejiang